Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients-Reference-Cited by-同舟云学术

Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients

Published:2015-09-11 Issue:5 Volume:171 Page:720-725
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

de Waal Esther G. M.¹,de Munck Linda²,Hoogendoorn Mels³,Woolthuis Gerhard⁴,van der Velden Annette⁵,Tromp Yvonne⁶,Vellenga Edo¹,Hovenga Sjoerd⁷

Affiliation:

1. Department of Haematology; University Medical Centre Groningen; Groningen The Netherlands

2. Department of Research; Netherlands Comprehensive Cancer Organisation; Utrecht The Netherlands

3. Department of Haematology; Medical Centre Leeuwarden; Leeuwarden The Netherlands

4. Department of Haematology; Antonius Hospital; Sneek The Netherlands

5. Department of Haematology; Martini Hospital; Groningen The Netherlands

6. Department of Haematology; Röpcke-Zweers Hospital; Hardenberg The Netherlands

7. Department of Haematology; Nij Smellinghe Hospital; Drachten The Netherlands

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13653/fullpdf

Reference16 articles.

1. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma;Attal;The New England journal of medicine,2012

2. The association of cyclophosphamide and dexamethasone in advanced refractory multiple myeloma patients;Celesti;Haematologica,1997

3. International uniform response criteria for multiple myeloma;Durie;Leukemia,2006

4. Combined Thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study;Hovenga;Annals of Hematology,2005

5. Improved longterm survival in multiple myeloma up to the age of 80 years;Kristinsson;Leukemia,2014

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives;Critical Reviews in Oncology/Hematology;2023-07

2. Continuous low-dose cyclophosphamide plus prednisone in the treatment of relapsed and refractory multiple myeloma with severe complications;Frontiers in Oncology;2023-05-22

3. Randomized phase II study of weekly carfilzomib 70 mg/m<sup>2</sup> and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients;Haematologica;2023-04-27

4. An update on the safety of ixazomib for the treatment of multiple myeloma;Expert Opinion on Drug Safety;2022-09-02

5. Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse;British Journal of Haematology;2020-01-02